FDA Adverse Event Other Summary report: N

VIKING

MDR report key: 2484931 · Received March 6, 2012

Report

Report Number
3008289288-2011-00003
Event Type
Other
Date Received
March 6, 2012
Date of Event
September 10, 2010
Report Date
March 9, 2011
Manufacturer
CAREFUSION 209 INC.
Product Code
IKN
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
PA, US
Reporter Occupation
OTHER HEALTH CARE PROFESSIONAL

Narratives

Additional Manufacturer Narrative · 1

CAREFUSION FIELD SERVICE ENGINEER WENT ON SITE IN (B)(4) 2008 AND OBSERVED THE FOLLOWING: IN NEW BUILDING, FOUND NO DEDICATED POWER LINES, GFI OUTLETS WERE TIED INTO THE SAME CIRCUIT OF THE VIKING MACHINES. WIRELESS ACCESS POINT OUTSIDE ROOM G5. ROOM LIGHTS AND BIOSONE ARE ELECTRICALLY NOISY, ALSO RECOMMENDED AGAINST ANY UNSHIELDED POWER DEVICES (RADIOS AND LIGHTS). RECOMMENDED SEPARATE DEDICATED CIRCUIT FOR ALL EMG MACHINES. RECOMMENDED AGAINST POWER STRIPS. VERIFIED ALL SYSTEMS AND THEY HAD GREAT BASELINE, NO NOISE WAS REPRODUCED UNLESS USING BAD AMPLIFIERS. CAREFUSION FIELD SERVICES ENGINEER AND SALES REP ARE VISITING THE CUSTOMER SITE ON (B)(4), 2011 TO DISCUSS THIS ISSUE. SENDING RESPONSES TO QUESTIONS ASKED BY FDA TO (B)(4).

Description of Event or Problem · 1

WHEN CUSTOMER IS PERFORMING A STANDARD ELECTROMYOGRAPHY STUDY (EMG), 60 CYCLE INTERFERENCE WILL OFTEN BE SO SIGNIFICANT THAT A VALID STUDY CANNOT BE COMPLETED. EQUIPMENT DOES HAVE 60HZ FILTERING, BUT PHYSICIANS DO NOT WANT TO DELETE THE INFO IN THIS RANGE. THIS HAS OCCURRED FREQUENTLY SINCE (B)(6) 2008 WHEN THE NEW BUILDING WAS BUILT. THE NATURE OF THE INTERFERENCE HAS BEEN DETERMINED TO BE RADIANT AND ATTRIBUTED TO THE BUILDING'S ELECTRICAL SYSTEMS: LIGHTING AND POWER DISTRIBUTION TO OTHER NEIGHBORING SERVICES. (B)(4). CAREFUSION DID NOT REPORT THIS EVENT BECAUSE THERE WAS NO DEATH OR SERIOUS INJURY OR THAT THE EQUIPMENT MALFUNCTIONED AND WOULD CAUSE DEATH OR SERIOUS INJURY.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 VIKING VIKING IKN CAREFUSION 209 INC. VARIOUS N/A NA

Patients

Seq Age Sex Outcome Treatment
1 Other